BREAST CANCER RESISTANCE PROTEIN - Drug Transporters: Molecular Characterization and Role in Drug Disposition - page 345

28. Locher, KP, Lee, AT, and Rees, DC. 2002. The E. coli BtuCD structure: a framework for
ABC transporter architecture and mechanism. Science 296:1091-1098.
29. Henriksen, U, Fog, JU, Litman, T, and Gether, U. 2005. Identification of intra- and
intermolecular disulfide bridges in the multidrug resistance transporter ABCG2. J Biol
Chem 280:36926-36934.
30. Diop, NK, and Hrycyna, CA. 2005. N-Linked glycosylation of the human ABC transporter
ABCG2 on asparagine 596 is not essential for expression, transport activity, or trafficking
to the plasma membrane. Biochemistry 44:5420-5429.
31. Li, YF, Polgar, O, Okada, M, Esser, L, Bates, SE and Xia, D. 2006. Towards understanding
the mechanism of action of the multidrug resistance-linked half-ABC transporter ABCG2:
a molecular modeling study. J Mol Graph Model 25:837-851.
32. Russ, WP, and Engelman, DM. 2000. The GxxxG motif: a framework for transmembrane
helix-helix association. J Mol Biol 296:911-919.
33. Gerber, D, and Shai, Y. 2001. In vivo detection of hetero-association of glycophorin-A
and its mutants within the membrane. J Biol Chem 276:31229-3132.
34. Polgar, O, Robey, RW, Morisaki, K, Dean, M, Michejda, C, Sauna, ZE, Ambudkar, SV,
Tarasova, N, and Bates, SE. 2004. Mutational analysis of ABCG2: role of the GXXXG
motif. Biochemistry 43:9448-9456.
35. Loo, TW, Bartlett, MC, and Clarke, DM. 2004. Disulfide cross-linking analysis shows
that transmembrane segments 5 and 8 of human P-glycoprotein are close together on the
cytoplasmic side of the membrane. J Biol Chem 279:7692-7697.
36. Xu, J, Liu, Y, Yang, Y, Bates, S, and Zhang, JT. 2004. Characterization of oligomeric
human half-ABC transporter ATP-binding cassette G2. J Biol Chem 279:19781-9.
37. Mackenzie, SM, Brooker, MR, Gill, TR, Cox, GB, Howells, AJ, and Ewart, GD. 1999.
Mutations in the white gene of Drosophila melanogaster affecting ABC transporters that
determine eye colouration. Biochim Biophys Acta 1419:173-185.
38. Polgar, O, Ozvegy-Laczka, C, Robey, RW, Morisaki, K, Okada, M, Tamaki, A, Koblos,
G, Elkind, NB, Ward, Y, Dean, M, Sarkadi, B, and Bates, SE. 2006. Mutational studies of
G553 in TM5 of ABCG2: a residue potentially involved in dimerization. Biochemistry.
39. Dey, S, Ramachandra, M, Pastan, I, Gottesman, MM, and Ambudkar, SV. 1997. Evidence
for two nonidentical drug-interaction sites in the human P-glycoprotein. Proc Natl Acad
SciUSA94:10594-10599.
40. Shapiro, AB, and Ling, V. 1997. Positively cooperative sites for drug transport by P-
glycoprotein with distinct drug specificities. Eur J Biochem 250:130-137.
41. Ejendal, KF, and Hrycyna, CA. 2005. Differential sensitivities of the human ATP-
binding cassette transporters ABCG2 and P-glycoprotein to cyclosporin A. Mol Phar-
macol 67:902-911.
42. Miwa, M, Tsukahara, S, Ishikawa, E, Asada, S, Imai, Y, and Sugimoto, Y. 2003. Single
amino acid substitutions in the transmembrane domains of breast cancer resistance protein
(BCRP) alter cross resistance patterns in transfectants. Int J Cancer 107:757-763.
43. Ozvegy-Laczka, C, Koblos, G, Sarkadi, B, and Varadi, A. 2005. Single amino acid (482)
variants of the ABCG2 multidrug transporter: major differences in transport capacity and
substrate recognition. Biochim Biophys Acta 1668:53-63.
44. Robey, RW, Honjo, Y, Morisaki, K, Nadjem, TA, Runge, S, Risbood, M, Poruchynsky,
MS, and Bates, SE. 2003. Mutations at amino acid 482 in the ABCG2 gene affect substrate
and antagonist specificity. Br J Cancer 89:1971-1978.